Patents by Inventor Lee Martin Greenberger

Lee Martin Greenberger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CANCERS WITH HER3 ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20120076781
    Abstract: One aspect of the invention provides methods for treating cancers which are resistant to treatment with a protein tyrosine kinase inhibitor by co-treatment with the protein tyrosine kinase inhibitor and one or more antisense oligomers that reduce the expression of HER3 and/or HER2 and/or EGFR. Another aspect of the invention provides methods for treating cancers by co-treatment with an inhibitor of HER2 and one or more antisense oligomers that reduce the expression of HER3.
    Type: Application
    Filed: April 14, 2010
    Publication date: March 29, 2012
    Applicants: ENZON PHARMACEUTICALS, INC.
    Inventors: Yixian Zhang, Zhengxing Qu, Lee Martin Greenberger
  • Reversal of multidrug resistance in human colon carcinoma cells
    Patent number: 6878737
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: April 12, 2005
    Assignee: Wyeth Holdings Corporation
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Lee Martin Greenberger
  • Method of treating resistant tumors
    Publication number: 20040121965
    Abstract: The invention provides a method of treating or inhibiting the growth of or eradicating a tumor in a mammal in need thereof wherein said tumor is resistant to at least one chemotherapeutic agent which method comprises providing to said mammal an effective amount of a compound of Formula II or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 18, 2003
    Publication date: June 24, 2004
    Applicant: Wyeth Holdings Corporation
    Inventors: Lee Martin Greenberger, Frank Loganzo, Carolyn Mary Discafani-Marro, Arie Zask, Semiramis Ayral-Kaloustian
  • Reversal of multidrug resistance in human colon carcinoma cells
    Publication number: 20030083230
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Application
    Filed: February 28, 2002
    Publication date: May 1, 2003
    Applicant: American Cyanamid Company
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Lee Martin Greenberger
  • Reversal of multidrug resistance in human colon carcinoma cells
    Patent number: 6537964
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Grant
    Filed: February 28, 2002
    Date of Patent: March 25, 2003
    Assignee: Wyeth Holdings Corporation
    Inventors: Haiyin He, Lee Martin Greenberger
  • Method of treating estrogen receptor positive carcinoma
    Patent number: 6511986
    Abstract: This invention provides a method of treating or inhibiting an estrogen receptor positive carcinoma in a mammal in need thereof, which comprises providing said mammal with an effective amount of a combination of a rapamycin and an antiestrogen.
    Type: Grant
    Filed: August 6, 2001
    Date of Patent: January 28, 2003
    Assignee: Wyeth
    Inventors: Yixian Zhang, Tammy M. Sadler, Philip Frost, Lee Martin Greenberger
  • Reversal of multidrug resistance in human colon carcinoma cells
    Publication number: 20020169111
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Application
    Filed: February 28, 2002
    Publication date: November 14, 2002
    Applicant: American Cyanamid Comany
    Inventors: Haiyin He, Lee Martin Greenberger
  • Reversal of multidrug resistance in human colon carcinoma cells
    Publication number: 20020156015
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Application
    Filed: February 28, 2002
    Publication date: October 24, 2002
    Applicant: American Cyanamid Company
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Maya Prakash Singh, Lee Martin Greenberger
  • Method of treating estrogen receptor positive carcinoma
    Publication number: 20020045638
    Abstract: This invention provides a method of treating or inhibiting an estrogen receptor positive carcinoma in a mammal in need thereof, which comprises providing said mammal with an effective amount of a combination of a rapamycin and an antiestrogen.
    Type: Application
    Filed: August 6, 2001
    Publication date: April 18, 2002
    Inventors: Yixian Zhang, Tammy M. Sadler, Philip Frost, Lee Martin Greenberger
  • Reversal of multidrug resistance in human colon carcinoma cells
    Patent number: 6372775
    Abstract: The present invention describes the use of fumitremorgin A, B and C and a series of diketopiperazines of Formula (I) to resensitize multidrug resistant (MDR) cancer cells to the cytotoxic effects of chemotherapeutic drugs.
    Type: Grant
    Filed: May 27, 1999
    Date of Patent: April 16, 2002
    Assignee: American Cyanamid Company
    Inventors: Sridhar Krishna Rabindran, Haiyin He, Lee Martin Greenberger